Ganna Blazhenets1, Lars Frings2, Yilong Ma2, Arnd Sörensen2, David Eidelberg2, Jens Wiltfang2, Philipp T Meyer2. 1. From the Department of Nuclear Medicine (G.B., L.F., A.S., P.T.M.), Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg; Center for Neurosciences (Y.M., D.E.), Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY; and Department of Psychiatry and Psychotherapy (J.W.), University Medical Center, Georg-August-University, Göttingen, Germany. ganna.blazhenets@uniklinik-freiburg.de. 2. From the Department of Nuclear Medicine (G.B., L.F., A.S., P.T.M.), Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg; Center for Neurosciences (Y.M., D.E.), Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY; and Department of Psychiatry and Psychotherapy (J.W.), University Medical Center, Georg-August-University, Göttingen, Germany.
Abstract
OBJECTIVE: To determine whether the Alzheimer disease (AD) dementia conversion-related pattern (ADCRP) on [18F]FDG PET can serve as a valid predictor for the development of AD dementia, the individual expression of the ADCRP (subject score) and its prognostic value were examined in patients with mild cognitive impairment (MCI) and biologically defined AD. METHODS: A total of 269 patients with available [18F]FDG PET, [18F]AV-45 PET, phosphorylated and total tau in CSF, and neurofilament light chain in plasma were included. Following the AT(N) classification scheme, where AD is defined biologically by in vivo biomarkers of β-amyloid (Aβ) deposition ("A") and pathologic tau ("T"), patients were categorized to the A-T-, A+T-, A+T+ (AD), and A-T+ groups. RESULTS: The mean subject score of the ADCRP was significantly higher in the A+T+ group compared to each of the other group (all p < 0.05) but was similar among the latter (all p > 0.1). Within the A+T+ group, the subject score of ADCRP was a significant predictor of conversion to dementia (hazard ratio, 2.02 per z score increase; p < 0.001), with higher predictive value than of alternative biomarkers of neurodegeneration (total tau and neurofilament light chain). Stratification of A+T+ patients by the subject score of ADCRP yielded well-separated groups of high, medium, and low conversion risks. CONCLUSIONS: The ADCRP is a valuable biomarker of neurodegeneration in patients with MCI and biologically defined AD. It shows great potential for stratifying the risk and estimating the time to conversion to dementia in patients with MCI and underlying AD (A+T+). CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that [18F]FDG PET predicts the development of AD dementia in individuals with MCI and underlying AD as defined by the AT(N) framework.
OBJECTIVE: To determine whether the Alzheimer disease (AD) dementia conversion-related pattern (ADCRP) on [18F]FDG PET can serve as a valid predictor for the development of AD dementia, the individual expression of the ADCRP (subject score) and its prognostic value were examined in patients with mild cognitive impairment (MCI) and biologically defined AD. METHODS: A total of 269 patients with available [18F]FDG PET, [18F]AV-45 PET, phosphorylated and total tau in CSF, and neurofilament light chain in plasma were included. Following the AT(N) classification scheme, where AD is defined biologically by in vivo biomarkers of β-amyloid (Aβ) deposition ("A") and pathologic tau ("T"), patients were categorized to the A-T-, A+T-, A+T+ (AD), and A-T+ groups. RESULTS: The mean subject score of the ADCRP was significantly higher in the A+T+ group compared to each of the other group (all p < 0.05) but was similar among the latter (all p > 0.1). Within the A+T+ group, the subject score of ADCRP was a significant predictor of conversion to dementia (hazard ratio, 2.02 per z score increase; p < 0.001), with higher predictive value than of alternative biomarkers of neurodegeneration (total tau and neurofilament light chain). Stratification of A+T+ patients by the subject score of ADCRP yielded well-separated groups of high, medium, and low conversion risks. CONCLUSIONS: The ADCRP is a valuable biomarker of neurodegeneration in patients with MCI and biologically defined AD. It shows great potential for stratifying the risk and estimating the time to conversion to dementia in patients with MCI and underlying AD (A+T+). CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that [18F]FDG PET predicts the development of AD dementia in individuals with MCI and underlying AD as defined by the AT(N) framework.
Authors: Abhinay D Joshi; Michael J Pontecorvo; Ming Lu; Daniel M Skovronsky; Mark A Mintun; Michael D Devous Journal: J Nucl Med Date: 2015-09-03 Impact factor: 10.057
Authors: Susan M Landau; Danielle Harvey; Cindee M Madison; Robert A Koeppe; Eric M Reiman; Norman L Foster; Michael W Weiner; William J Jagust Journal: Neurobiol Aging Date: 2009-08-05 Impact factor: 4.673
Authors: S Kim; S Swaminathan; L Shen; S L Risacher; K Nho; T Foroud; L M Shaw; J Q Trojanowski; S G Potkin; M J Huentelman; D W Craig; B M DeChairo; P S Aisen; R C Petersen; M W Weiner; A J Saykin Journal: Neurology Date: 2010-12-01 Impact factor: 9.910
Authors: Philipp T Meyer; Sabine Hellwig; Florian Amtage; Christof Rottenburger; Ursula Sahm; Peter Reuland; Wolfgang A Weber; Michael Hüll Journal: J Nucl Med Date: 2011-02-14 Impact factor: 10.057
Authors: Ingrid S van Maurik; Stephanie J Vos; Isabelle Bos; Femke H Bouwman; Charlotte E Teunissen; Philip Scheltens; Frederik Barkhof; Lutz Frolich; Johannes Kornhuber; Jens Wiltfang; Wolfgang Maier; Oliver Peters; Eckart Rüther; Flavio Nobili; Giovanni B Frisoni; Luiza Spiru; Yvonne Freund-Levi; Asa K Wallin; Harald Hampel; Hilkka Soininen; Magda Tsolaki; Frans Verhey; Iwona Kłoszewska; Patrizia Mecocci; Bruno Vellas; Simon Lovestone; Samantha Galluzzi; Sanna-Kaisa Herukka; Isabel Santana; Ines Baldeiras; Alexandre de Mendonça; Dina Silva; Gael Chetelat; Stephanie Egret; Sebastian Palmqvist; Oskar Hansson; Pieter Jelle Visser; Johannes Berkhof; Wiesje M van der Flier Journal: Lancet Neurol Date: 2019-09-13 Impact factor: 44.182
Authors: Paul J Mattis; Martin Niethammer; Wataru Sako; Chris C Tang; Amir Nazem; Marc L Gordon; Vicky Brandt; Vijay Dhawan; David Eidelberg Journal: Neurology Date: 2016-10-05 Impact factor: 9.910
Authors: George Crișan; Nastasia Sanda Moldovean-Cioroianu; Diana-Gabriela Timaru; Gabriel Andrieș; Călin Căinap; Vasile Chiș Journal: Int J Mol Sci Date: 2022-04-30 Impact factor: 6.208